Image

Global Osteosarcoma Market – Industry Trends and Forecast to 2030

Medical Devices

Image

Global Osteosarcoma Market – Industry Trends and Forecast to 2030

  • Medical Devices
  • Upcoming Report
  • Sep 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Osteosarcoma Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2023
Diagram Market Size (Base Year) USD 584.14 Million
Diagram Market Size (Forecast Year) USD 937.34 Million
Diagram CAGR %

Major Markets Players

  • Pfizer
  • Mylan N.V.
  • Novartis AG
  • Hikma Pharmaceuticals plc
  • Aurobindo Pharma

Global Osteosarcoma Market, By Type (Intramedullary Osteosarcoma, Juxtacortical Osteosarcoma, Extraskeletal Osteosarcoma), Diagnosis and Treatment (Treatment, Diagnosis), End-User (Hospitals and Clinics, Diagnostic Centers, Academic and Research Organizations) – Industry Trends and Forecast to 2030.

Osteosarcoma Market

Osteosarcoma Market Analysis and Size

Rising awareness amongst people is the vital factor escalating the market growth, also rise in research and development activities to launch a better treatment for osteosarcoma by leading players, rising government support for research and development, rising demand for new treatment of rare cancers such as osteosarcoma and increasing healthcare expenditure in some parts of the world are the major factors among others driving the acetaminophen (Paracetamol) market. Moreover, rising technological advancements and modernization in the healthcare devices, rising research and development activities in the healthcare sector and rising emerging markets with increasing geriatric population base will further create new opportunities for osteosarcoma market in the forecasted period.

Data Bridge Market Research analyses that the osteosarcoma market which was USD 584.14 million in 2022, would rocket up to USD 937.34 million by 2030, and is expected to undergo a CAGR of 8.33% during the forecast period. This indicates that the market value. “Intramedullary Osteosarcoma” dominates the type segment of the Osteosarcoma market owing rising technological advancement. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Osteosarcoma Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Intramedullary Osteosarcoma, Juxtacortical Osteosarcoma, Extraskeletal Osteosarcoma), Diagnosis and Treatment (Treatment, Diagnosis), End-User (Hospitals and Clinics, Diagnostic Centers, Academic and Research Organizations)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America)

Market Players Covered

Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), Melinta Therapeutics, Inc (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Lilly (U.S.), AstraZeneca (U.K.), Amgen Inc. (U.S.), Bellicum Phamaceuticals, Inc (U.S.), Incyte (U.S.), Nektar Therapeutics (U.S.), Iovance Biotherapeutics (U.S.), Aurora biopharma (U.S.), BioAtla (U.S.), Eleison Pharmaceuticals (U.S.)  and Acrotech Biopharma, Inc. (U.S.) among others)

Market Opportunities

  • Technological advancement
  • Strategic partnerships and collaborations:
  • Rising healthcare expenditure

Market Definition

Osteosarcoma or osteogenic sarcoma is the most common type of bone cancer, which develops in the cells that forms new bone tissues. Osteosarcoma most commonly occurs in the long bones of the body such as long bones of the hands or legs, although it can occur in any bone of the body. Symptoms of osteosarcoma include swelling and localized bone pain.

Global Osteosarcoma Market Dynamics

Drivers

  • Increasing Incidence of Osteosarcoma

Osteosarcoma is one of the most common primary bone tumors, primarily affecting children and adolescents. The rising incidence of osteosarcoma globally is driving the demand for effective diagnosis, treatment, and management options

  • Growing Focus on Precision Medicine

Precision medicine involves tailoring treatment strategies based on an individual's genetic profile, tumor characteristics, and overall health. The growing focus on precision medicine has led to the identification of specific genetic alterations and biomarkers in osteosarcoma, enabling targeted therapies and personalized treatment plans

  • Innovations in Treatment Approaches

There have been significant advancements in the treatment of osteosarcoma, including surgical procedures, chemotherapy, targeted therapies, and radiation therapy. The development of novel treatment approaches, such as immunotherapy and personalized medicine, has shown promising results in improving survival rates and reducing treatment-related side effects

  • Government Initiatives and Funding

Government initiatives aimed at improving cancer care, research funding, and healthcare infrastructure have contributed to the growth of the global osteosarcoma market. Increased funding allows for the development of new therapies, clinical trials, and the establishment of specialized centers for the diagnosis and treatment of osteosarcoma

Opportunities

  • Rising Healthcare Expenditure

Increasing healthcare expenditure across the globe has positively impacted the osteosarcoma market. Higher healthcare spending allows for better infrastructure, improved access to healthcare services, and increased adoption of advanced treatment options, ultimately driving market growth

  • Advancements in Diagnostic Technologies

Advances in diagnostic technologies, such as imaging techniques (X-ray, MRI, CT scans), molecular testing, and biopsy procedures, have improved the early detection and accurate diagnosis of osteosarcoma. These advancements have led to increased awareness, early intervention and improved patient outcomes

Restraints/Challenges

  • High Cost of Treatment

The cost of osteosarcoma treatment can be substantial, including surgery, chemotherapy, radiation therapy, and supportive care. These expenses can place a significant financial burden on patients and their families. The high cost of treatment may limit access to advanced therapies and comprehensive care, particularly in low-income regions or countries with inadequate healthcare coverage

  • Adverse Effects of Treatment

Osteosarcoma treatment, particularly chemotherapy and radiation therapy, can have significant side effects. These may include nausea, hair loss, fatigue, weakened immune system, and long-term complications such as organ damage. The potential for adverse effects can impact patient compliance with treatment regimens and quality of life

This osteosarcoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the osteosarcoma market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Developments

  • In December 2021, the Centers for Devices and Radiological Health of the FDA granted ZetaMet's breakthrough device for the treatment of metastatic bone cancers and osteological interventions
  •  In October 2020, Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals Inc. acquisition to provide additional potential in various diseases, including infectious diseases and vaccines, neuroscience, oncology and pulmonary hypertension

Global Osteosarcoma Market Scope

The osteosarcoma market is segmented on the basis of type, diagnosis and treatment and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Intramedullary Osteosarcoma
  • Juxtacortical Osteosarcoma
  • Extraskeletal Osteosarcoma

Diagnosis and Treatment

  • Treatment
  • Diagnosis

End-User

  • Hospitals and Clinics
  • Diagnostic Centers
  • Academic and Research Organizations

Osteosarcoma Market Regional Analysis/Insights

The osteosarcoma market is analysed and market size insights and trends are provided by country, type, diagnosis and treatment and end-user as referenced above.

The countries covered in the  osteosarcoma market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the osteosarcoma market because of the strong base of healthcare facilities, strong presence of major players in the market, increasing incidence of osteosarcoma and rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period from 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Osteosarcoma Market Share Analysis

The osteosarcoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to osteosarcoma market.

Some of the major players operating in the osteosarcoma market are

  • Pfizer Inc (U.S.)
  • Mylan N.V. (U.S.)
  • Novartis AG (Switzerland.)
  • Hikma Pharmaceuticals plc (U.K.)
  • Aurobindo Pharma (India)
  • Melinta Therapeutics, Inc (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • GSK plc. (U.K.)
  • Bayer AG (Germany)
  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • Lilly (U.S.)
  • Amgen Inc. (U.S.)
  • Bellicum Phamaceuticals, Inc (U.S.)
  • Incyte (U.S.)
  • Nektar Therapeutics (U.S.)
  • Iovance Biotherapeutics (U.S.)
  • Aurora biopharma (U.S.)
  • BioAtla (U.S.)
  • Acrotech Biopharma, Inc. (U.S.)
  • Eleison Pharmaceuticals (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The osteosarcoma market size will be worth USD 937.34 million by 2030.
The growth rate of the osteosarcoma market is 5.82% in the forecast period by 2030.
Increasing incidence of osteosarcoma, growing focus on precision medicine, innovations in treatment approaches & government initiatives and funding are the growth drivers of the osteosarcoma market.
Type, diagnosis and treatment and end-user are the factors on which the osteosarcoma market research is based.
Major companies in the osteosarcoma market are Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), Melinta Therapeutics, Inc (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Lilly (U.S.), AstraZeneca (U.K.), Amgen Inc. (U.S.), Bellicum Phamaceuticals, Inc (U.S.), Incyte (U.S.), Nektar Therapeutics (U.S.), Iovance Biotherapeutics (U.S.), Aurora biopharma (U.S.), BioAtla (U.S.), Eleison Pharmaceuticals (U.S.) and Acrotech Biopharma, Inc. (U.S.) among others).
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials